Gilead Sciences reported survey findings on PrEP access and utilization in the US during COVID-19 shelter-in-place orders
On Jul. 8, 2020, Gilead Sciences announced data evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP…
-
-
Oxford COVID-19 study reported face masks work, call for immediate adoption
On Jul. 8, 2020, a study from Oxford’s Leverhulme Centre for Demographic Science reported that cloth face coverings,…
-
Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)
On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…
-
Constant Therapeutics’ TXA127 tested in multiple clinical trials for COVID-19 patients
On Jul. 8, 2020, Constant Therapeutics reported that its peptide drug TXA127 was tested in a series of…
-
BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns
On Jul. 8, 2020, BD (Becton, Dickinson) announced the formation of a strategic, public-private partnership with the Biomedical…
-
Fred Hutch joined international COVID-19 vaccine effort
On Jul. 8, 2020, the Fred Hutchinson Cancer Research Center was named the coordinating center for vaccine clinical…
-
Biotechnology | Clinical Research | COVID-19 | Infectious Disease | NIH | Non-Profit Research | Therapeutics | Vaccine
NIH launched clinical trials network to test COVID-19 vaccines and other prevention tools
On Jul. 8, 2020, the National Institute of Allergy and Infectious Diseases announced it had established a new…
-
Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19
On Jul. 8, 2020, scientists from Texas A&M University, biopharmaceutical company Pulmotect and MD Anderson Cancer Center announced…
-
GSK and Medicago announced collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
On Jul. 7, 2020, GlaxoSmithKline and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine…
-
Cerus reported successful inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma
On Jul. 7, 2020, Cerus announced study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative…
-
In vitro testing of Innovation Pharmas’ Brilacidin for COVID-19 showed consistent anti-SARS-CoV-2 efficacy
On Jul. 7, 2020, Innovation Pharma reported the latest developments related to research into Brilacidin as a potential…
-
Novavax announced $1.6 billion funding from Operation Warp Speed
On Jul. 7, 2020, Novavax announced that it had been selected to participate in Operation Warp Speed, a…
-
LabCorp launched first digital COVID-19 service that improves the doctor and patient experience
On Jul. 7, 2020, LabCorp launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital…
-
Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail
On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…
-
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
-
AIM ImmunoTech signed material transfer and research agreement with Japan’s National Institute of Infectious Diseases and Shionogi & Co to test Ampligen as potential vaccine adjuvant for COVID-19
On Jul. 6, 2020, AIM ImmunoTech announced that it had signed a material transfer and research agreement with…
-
BD launched portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes, expanding access to COVID-19 testing
On Jul. 6, 2020, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) had granted Emergency…
-
Regeneron announced start of REGN-COV2 phase 3 COVID-19 prevention trial in collaboration with National Institute of Allergy and Infectious Diseases
On Jul. 6, 2020, Regeneron announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody…
-
Biotechnology | COVID-19 | Disease | HIV | Infectious Disease | Therapeutics | WHO
Access to HIV medicines severely impacted by COVID-19 as AIDS response stalled
On Jul. 6, 2020, seventy-three countries warned that they were at risk of stock-outs of antiretroviral (ARV) medicines…
-
Mylan secured regulatory approval for remdesivir lyophilized powder for injection 100 mg/vial in India for restricted emergency use in COVID-19 patients
On Jul. 6, 2020, Mylan announced that the Drug Controller General of India (DCGI) has approved its remdesivir…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | Influenza | Vaccine
The FDA issued an emergency use authorization for the third diagnostic test for detection and differentiation of the viruses that cause flu and COVID-19
On Jul. 6, 2020, the U.S. Food and Drug Administration (FDA) announced it had issued an emergency use…
-
Ignoring airborne COVID spread risky
On Jul. 6, 2020, the lack of universal recognition that COVID-19 is transmitted via airborne particles, along with…
-
Sinovac COVID-19 vaccine collaboration with Butantan received approval from Brazilian regulator for phase III trial
On Jul. 6, 2020, Sinovac Biotech announced an update to its previously announced partnership with Butantan, a leading…
-
Immune Regulation partnered with DynPort Vaccine to advance drug product for COVID-19 into clinical trials
On Jul. 9, 2020, Altimmune announced that it had entered into a teaming agreement with DynPort Vaccine Company…
-
Emergent BioSolutions signed five-year agreement for large-scale drug substance manufacturing for Johnson & Johnson’s COVID-19 vaccine candidate
On Jul. 6, 2020, Emergent BioSolutions announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, a Johnson &…
-
Anixa Biosciences and OntoChem announced completion of initial screening program and identification of additional Covid-19 compounds
On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had completed the initial in silico…
-
WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
On Jul. 4, 2020, the World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering…
-
EC granted conditional Marketing Authorization for Gilead’s Veklury (remdesivir) for treatment of COVID-19
On Jul. 3, 2020, the European Commission granted a conditional Marketing Authorisation (MA) in respect of Gilead’s Veklury…
-
CytoDyn announced exclusive agreement for distribution and supply of leronlimab for treatment of COVID-19 in U.S.
On Jul. 3, 2020, CytoDyn announced it had signed an exclusive Distribution and Supply Agreement with American Regent…
